Cyberknife Radiosurgery and Quality of Life

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Stanford University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01163539
First received: July 14, 2010
Last updated: July 16, 2012
Last verified: July 2012
  Purpose

The purpose of this study is to look at pain control and QOL improvement after treatment with CK Radiosurgery for spinal metastases.


Condition
Bone Cancer
Central Nervous System Cancer

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: Cyberknife Radiosurgery and Quality of Life

Resource links provided by NLM:


Further study details as provided by Stanford University:

Estimated Enrollment: 70
Study Start Date: September 2010
Estimated Study Completion Date: September 2012
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patient must have cancer metastases to the spine. They may have had previous surgical or not surgical treatments. Benign tumors will not be assessed.

Criteria

Inclusion Criteria:

  • Patients with a spinal metastasis who will be treated with Cyberknife radiosurgery.
  • There are no age or gender restrictions.
  • There are no life expectancy restrictions.
  • Karnofsky Performance Status greater than 40.
  • Negative pregnancy test or clinically assessed as not pregnant.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients with benign tumors will not be included (neurofibromas, schwannomas, etc.)
  • Other investigational medications or treatments will be noted, but will not preclude inclusion.
  • Pregnant or nursing patients will be not be included in the study due to radiation exposure.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01163539

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Steven Daniel Chang Stanford University
  More Information

No publications provided

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01163539     History of Changes
Other Study ID Numbers: SPN0002, SU-07092010-6499
Study First Received: July 14, 2010
Last Updated: July 16, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms
Neoplasms by Site
Nervous System Diseases

ClinicalTrials.gov processed this record on October 23, 2014